global biopharmaceutical CMO & CRO market was valued at USD XX Bn in 2019 and is expected to reach USD XX Bn by2027, with a CAGR of XX% during the forecast period.
Biopharmaceuticals are medical drugs produced using biotechnology, that is, therapeutic products created through the genetic manipulation of living cells or organisms. Contract research organizations (CROs) are essential to the pharma, biotech, and MedTech industries. They are working with clients to test, refine, and market the latest pharmaceuticals and medical devices. Contract manufacturing organizations (CMOs) is a form of outsourcing where a manufacturer enters a formal agreement with another manufacturing firm for its parts, products, or component.
The report on the Global biopharmaceutical CMO & CRO Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecast period from 2019 to 2027. The market is divided into various segments like source, service type, and region with an in-depth outlook of the competitors and a listing of the profiled key players.
Some of the major key players in the global market include Lonza, Rentschler Biotechnologie GmbH, Boehringer Ingelheim GmbH, and JRS Pharma. The market size in terms of revenue and volume is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Global Biopharmaceutical CMO & CRO Market Dynamics
Biopharmaceuticals have been growing at a much faster rate than the traditional pharmaceutical industry in recent years and the trend is continuing. The remarkable increase in life expectancy and the major achievements in medical care over the past several decades by biopharmaceutical and biotechnology sectors are showing exponential growth in terms of novel technology and applications in recent years.
Several revolutionary milestones have been surpassed in the development of new drugs, antibodies, recombinant proteins, gene-editing technology, and much more to be explored. This creates potential to grow the biopharmaceutical CMO & CRO market. Launches of new efficient blockbuster bio products as well as maintenance of healthy pricing mechanism to ensure profits and the balanced approach in the supply chain has led biopharmaceutical companies to adopt the business strategy of optimizing manufacturing capacity through outsourcing.
The global biopharmaceutical CMO & CRO market has expanded rapidly owing to the significantly higher clinical success rate of biopharmaceuticals compared with new small-molecule chemical entities, their greater potential for curing diseases rather than just treating symptoms, and their greater efficacy with reduced side effects. A variety of new expression systems have been developed for recombinant protein production by using the basic aspect and component of the expression systems used in biopharmaceutical manufacturing.
The companies with biomanufacturing sites or who have the resources to build in-house capacity have adopted various manufacturing strategies depending on their specific situation. The build in-house capacity and strategies of pharmaceutical and biotechnology companies, help them to grow their outsource production.
The increase in the biopharmaceutical pipeline, growth in cell and gene therapies, and the increase in small biotechnology companies with no in-house manufacturing are the trends which were adopted by biomanufacturing directors at pharmaceutical and biotechnology companies, hence this development in the era of pharmaceutical industry help to grow the global market. Another reason for continuing global biopharmaceutical CMO & CRO market growth is the participation & investment of CMOs to meet variable demand and gain access to other capabilities. Continuing industry consolidation that is the exposure of new CMOs and their attention to becoming more specialized in the global market is the factor driving the global biopharmaceutical market.
Focus of biopharmaceutical manufacturers on certain product phase, customer size or technologies and flexible manufacturing to meet the demand of rapidly discovered therapeutics that target a smaller patient population. The biopharmaceutical CMOs are adopting new process technologies to help solve some of the challenges faced during managing multiple products that requiring rapid changeovers to support faster timelines. These all above factors contributing to driving global biopharmaceutical CMO & CRO market during the forecast period 2019-2027.
Apart from factors associated with pricing and profits, the advanced skills and complexity involved in drug manufacturing in the biopharma sector is hampering the growth of the global market. Another factor that may restrain the global market growth is, several novels revolutionary technologies such as adoptive cell transfer and gene therapy, which come with unique manufacturing challenges.
The global biopharmaceutical CMO & CRO market is segmented into source, service, and region.
By Source
• Mammalian
• Non-mammalian
Global Biopharmaceutical CMO & CRO Market
Mammalian cells are desired expression systems for biopharmaceuticals CMO & CRO and held the largest share of XX% in 2020.
Mammalian cells are the preferred hosts for the production of most complex protein therapeutics, since their functionally and pharmacokinetically relevant modifications are highly human-compatible. Mammalian cell lines are the dominant production systems for the manufacturing of large molecules as well as it has capabilities to add human-like post-translational modifications to complex protein therapeutics.
Mammalian cells have the dominant system for producing recombinant protein products for clinical application because of their capacity to properly fold and assemble proteins. This all features given by mammalian cell lines make their greater use in biopharmaceutical CROs & CMOs.
The use of the mammalian cell in the introduction of novel, robust, enhanced expression systems gives the improved process monitoring solution. Adoption of recently developed mammalian cell line engineering tools and automated screening methods and disposable devices are helping this segment to grow the global market in the forecast period. These developments have led to the more productive and efficient manufacturing of biologics using mammalian cells.
High yielding capacity and desired product quality is given by these cell lines during the therapeutics manufacturing are helping to hold the dominant position of this segment during the forecast period.
Non-Mammalian segment is expected to command second largest market share of xx% by 2027.
Innovative strategies are implemented in non-mammalian cell lines to identify and explore the potential of various microbes. This, in turn, is expected to contribute to the lucrative growth of the non-mammalian biopharmaceutical manufacturing segment.
By Service Type
• Contract Manufacturing
• Contract Research
The contract manufacturing segment was estimated at 12.14 billion USD in 2019 and is expected to exhibit a compounded annual growth rate (CAGR) of 7.5% during the forecast period of a report from 2019-2027.
The biopharmaceutical contract manufacturing continues its upward trajectory, as pharmaceutical and biotechnology companies increase their spending for outsourced services. This growth results from the expanded use of biopharmaceuticals, new biopharmaceutical approvals and new biopharmaceutical development programs.
Contract manufacturing will significantly contribute to the overall industry’s growth, as domestic (bio)pharmaceutical research companies, which had been forced to fund and manage their own production lines, are now allowed to use contract manufacturers - who can typically perform critical manufacturing functions more efficiently. This is especially important for many early-stage drug innovators.
Contract Manufacturing Organizations (CMO) have been fulfilling the requirement of the pharmaceutical organizations by providing competitive services from drug manufacturing to aseptic filling, and have been a pivotal reason behind the success of the biopharmaceutical industry.
The CMOs have several reasons for their optimistic outlook. These reasons include an increase in small, well-funded virtual biotechnology companies, higher demand for production services supporting cell and gene therapies, and higher growth in Asia.
Offerings are given by production & development and ancillary services by biopharmaceutical contract manufacturers show the steady global market growth during the forecast period.
Many CMOs have increased their capacity either by constructing new facilities or acquiring biomanufacturing facilities from pharmaceutical and biotechnology companies. Additionally, CMOs are also adding capacity at smaller scales through their investment in single-use bioreactors. Single-use bioreactor capacity is now widely accepted, and it is a preferred production mode for biopharmaceuticals that target smaller patient populations.
The great investment of CMOs
The global CMOs are investing in cell and gene therapy production capacity, analytic capabilities, new research centers, and productivity & quality enhancements. The productivity and quality enhancements include continuous manufacturing, perfusion systems, and tangential flow filtration and membrane technologies.
By Region
• North America
• Europe
• Asia-Pacific
• MEA & Africa
• Latin America
Global Biopharmaceutical CMO & CRO Market1
Asia Pacific is expected to command largest market share of XX% by 2027.
Developing Domestic Biologics Pipelines in Asia Pacific
The development of biologics pipelines by domestic companies will drive the business of biopharmaceutical contract manufacturing in China. China will become the single-most dominant player in Asia in terms of biopharmaceutical CMOs and overall biopharmaceutical manufacturing capacity. China biopharma companies are adopting open-minded plans which are focusing on single-use technology. Asia Pacific is making coordinated progress, involving the rapid expansion of manufacturing capacity and fixing quality issues. More improvement in biopharmaceutical infrastructure and fastest-growing economy with addressed quality maintenance during GMP processes.
Government coordination of planning and funding for pharmaceutical and biotechnological organizations are driving the growth of global market from the Asia Pacific. Strict regulations and guidelines from FDA in new product launches help to achieve the quality level for manufacturing & product development processes in biopharmaceutical organizations.
Key Players Operating in Global Biopharmaceutical CMO & CRO Market
• Lonza
• Rentschler Biopharma SE
• Boehringer Ingelheim GmbH
• JRS Pharma
• Inno Biologics Sdn Bhd
• ProBioGen AG
• BIOMEVA GmbH
• FUJIFILM Diosynth Biotechnologies Inc
• Samsung BioLogics
• TOYOBO Biologics CO. LTD.
• CMC Biologics
• Patheon
• AbbVie Inc.
• Binex Co. Ltd.
• WuXi Biologics
• ACG Biologics
• PRA Health Sciences Inc
• Samsung BioLogics
For more information of visit:https://www.maximizemarketresearch.com/market-report/global-biopharmaceutical-cmo-cro-market/83003/
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
